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Abstract
Background: An important aspect of the link between estrogen and breast cancer is whether urinary estrogen
levels are representative of the intra-tissue levels of bioavailable estrogens.
Methods: This study compares 15 estrogen and estrogen metabolite levels in breast tissue and urine of 9 women
with primary breast cancer using a quantitative liquid chromatography-mass spectrometry method.
Results: The average levels of estrogens (estrone, 17 beta-estradiol) were significantly higher in breast tissue than
in urine. Both the 2 and the 16-hydroxylation pathways were less represented in breast tissue than urine; no
components of the 4-hydroxypathway were detected in breast tissue, while 4-hydroxyestrone was measured in
urine. However, the 2/16 ratio was similar in urine and breast tissue. Women carrying the variant CYP1B1 genotype
(Leu/Val and Val/Val) showed significantly lower overall estrogen metabolite, estrogen, and 16-hydroxylation
pathway levels in breast tissue in comparison to women carrying the wild type genotype. No effect of the CYP1B1
polymorphism was observed in urinary metabolites.
Conclusions: The urinary 2/16 ratio seems a good approximation of the ratio observed in breast tissue. Metabolic
genes may have an important role in the estrogen metabolism locally in tissues where the gene is expressed, a
role that is not readily observable when urinary measurements are performed.
Background
A woman’s lifetime exposure to estrogens has been
widely accepted as a risk factor for breast cancer [1-3].
Proposed mechanisms for the association include the
ability of estrogens to induce breast cell proliferation,
stimulate cell division [4,5], and increase oxidative
damage with a direct genotoxic effect [6].
Estrogen metabolites have also been extensively stu-
died as breast cancer risk factors. This process involves
an oxidative pathway, beginning with the conversion of
estradiol to estrone, and continues through hydroxyla-
tion at sites C2, C4 or C-16 [6]. Both 2-OHE1 and
16a-OHE1 are estrogen-like compounds, however, the
16a-OHE1 metabolite is a potent estrogenic molecule
that activates the ER and induces proliferation of cul-
tured breast cancer cells by 40%, whereas the 2-OHE1
metabolite has very little estrogen receptor binding affi-
nity (< 0.1% compared to estradiol) [7], and has been
shown to decrease cell proliferation by 20 to 30% in
cultured breast cancer cell lines [8,9]. Components of
the 4-hydroxylation pathway also have been shown to
be genotoxic [7,10]; the 4OHE1 metabolite is thought to
be strongly estrogenic and potentially carcinogenic, yet
quantitatively its production is generally less than 15%
of the production of 2OHE1 [7].
Although limited research has been conducted in
humans on the effects on estrogen metabolites of meta-
bolic gene polymorphisms involved in estrogen metabo-
lism, a common CYP1B1 polymorphism (Val432Leu)
has been shown to influence the 2/16 ratio in healthy
women, possibly by catalyzing the formation of the 2
hydroxyl group [11].
Several epidemiological studies have investigated the
association between 2-OHE1 and 16a-OHE1 levels and
breast cancer [12-23]. While the prevailing hypothesis
suggests that a higher 2-OHE1 to 16a-OHE1 ratio
would predict a lower breast cancer risk, the results
have been inconsistent. Methodological reasons such
as the variability of estrogen levels and metabolism
across the menstrual cycle, the effect of both genetic
and environmental factors on estrogen production and
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metabolism, and the use of urine or serum measure-
ments as surrogate markers of breast tissue estrogen
metabolism, may be the basis of the varying results pro-
vided by the different studies.
An important aspect of the link between estrogen levels
and breast cancer risk that has not been addressed is
whether urinary and plasma estrogen metabolite levels
are representative of the intra-tissue levels of bioavailable
estrogens. Human breast tissue estrogens levels have
been reported to be much higher than their respective
plasma values, and several key enzymes involved in ster-
oid metabolism are specifically expressed in both normal
and malignant human breast tissues [24-27].
The present study compares estrogen and estrogen
metabolite levels in breast tissue and urine of women
who were diagnosed with primary breast cancer using a
quantitative liquid chromatography-mass spectrometry
method. The role of one of the metabolic genes involved
in estrogen metabolism, CYP1B1, is also studied.
Methods
Breast tissue and urine sample collection
Women who were diagnosed with primary, incident
breast cancer pathologically confirmed at Magee-
Women’s Hospital at the University of Pittsburgh during
the period 2006-2008 were asked to answer questions
from a standardized survey including data on family his-
tory of cancer, smoking history, and alcohol use.
Patients’ height and weight were obtained to calculate
their BMI. Clinical annotations were extracted from
electronic medical records.
Morning spot urine samples were obtained at the time
of visit, pre-surgery/pre-therapy, preserved by addition
of 400 mg ascorbic acid and frozen at -20°C after collec-
tion. None of the subjects had received estrogen-
containing treatment for at least 3 months prior to
urine sample collection. Informed consent was obtained
from each patient prior to survey administration, sample
collection and linkage to the breast tissue specimen col-
lected at surgery. Study procedures were approved by
the University of Pittsburgh Medical Center Institutional
Board.
Breast tissues samples were snap frozen at the time of
surgery, and stored in liquid nitrogen. To reduce varia-
bility due to personal characteristics, only samples from
white women who declared themselves to be never smo-
kers were considered eligible. Among the eligible
women, a stratified random sample was extracted
according to CYP1B1 genotype. The final sample pre-
sented in this study consisted of 9 women.
Sample preparations
Sample preparations for urine samples and breast tissues
were conducted as previously described [28,29].
Unconjugated estrogens were extracted from human
samples using dichloromethane. The SI-EM internal
standards were incorporated at the beginning stages of
sample preparations to compensate for the potential loss
of any EM during sample manipulations. Extracted EM
and SI-EM were dansylated prior to liquid spectrometry
analyses.
Laboratory methods
Fifteen estrogen metabolites (EM) [estrone (E1), estradiol
(E2), estriol (E3), 16-epiestriol (16-epiE3), 17-epiestriol
(17-epiE3), 16-ketoestradiol (16-ketoE2), 16a-hydroxyes-
trone (16a-OHE1), 2-methoxyestrone (2-MeOE1), 4-
methoxyestrone (4-MeOE1), 2-hydroxyestrone-3-methyl
ether (3-MeOE1), 2-methoxyestradiol (2-MeOE2),
4-methoxyestradiol (4-MeOE2), 2-hydroxyestrone (2-
OHE1), 4-hydroxyestrone (4-OHE1), and 2-hydroxyestra-
diol (2-OHE2)] were obtained from Steraloids, Inc.
(Newport, RI). Stable isotope labeled estrogens (SI-EM)
estradiol-13,14,15,16,17,18-13C6 (
13C6-E2) and estrone-
13,14,15,16,17,18-13C6 (
13C6-E1) were purchased from
Cambridge Isotope Laboratories, Inc. (Andover, MA).
The SI-EM estriol-2,4,17-d3 (d3-E3), 2-hydroxyestradiol-
1,4,16,16,17-d5 (d5-2-OHE2), and 2-methoxyestradiol-
1,4,16,16,17-d5 (d5-2-MeOE2), were obtained from C/D/
N Isotopes, Inc. (Pointe-Claire, Quebec, Canada), and
16-epiestriol-2,4,16-d3 (d3-16-epiE3) was purchased from
Medical Isotopes, Inc. (Pelham, NH). These analytical
standards have reported chemical and isotopic purity
≥98%. Dichloromethane and methanol were obtained
from EMD Merck KGaA (Darmstadt, Germany).
Sodium hydroxide and sodium acetate were purchased
from Fisher Scientific (Fair Lawn, NJ). Glacial acetic
acid, formic acid, sodium bicarbonate, L-ascorbic acid
were obtained from Sigma Chemical Co. (St. Louis,
MO). Dansyl chloride and acetone were purchased from
Aldrich Chemical Co. (Milwaukee, WI). All chemicals
and solvents utilized in these experiments were high
purity or HPLC grade.
Liquid Chromatography-Tandem Mass Spectrometry (LC-
MS2)
Capillary LC-MS2 analysis was conducted using an Agi-
lent 1200 series nanoflow LC system (Agilent Technolo-
gies, Palo Alto, CA) coupled to a TSQ™ Quantum Ultra
triple quadrupole mass spectrometer (Thermo Electron,
San Jose, CA). The LC separation was carried out using a
150 mm long × 300 μm i.d. column packed with 4 μm
Synergi Hydro-RP particles (Phenomenex, Torrance, CA)
maintained at 40°C. Eight microliters of each sample was
injected onto the column. The mobile phase, operating at
a flow rate of 4 μL/min, consisted of methanol as solvent
A and 0.1% (v/v) formic acid in water as solvent B. A lin-
ear gradient from 72-85% solvent B in 75 min. was used
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to resolve the EM and SI-EM. Mass spectrometry condi-
tions were as follows: source: ESI; ion polarity: positive;
spray voltage: 3500 V; sheath and auxiliary gas: nitrogen;
sheath gas pressure: 7 arbitrary units; ion transfer capil-
lary temperature, 270°C; scan type: selected reaction
monitoring (SRM); collision gas: argon; collision gas
pressure: 1.5 mTorr; scan width: 0.7 u; scan time: 0.50 s;
Q1 peak width: 0.70 u full-width half-maximum
(FWHM); Q3 peak width: 0.70 u FWHM. The optimized
SRM conditions for the protonated molecules [MH]+ of
EM-Dansyl and SI-EM-Dansyl were similar to those pre-
viously described [28,29].
Quantitation of estrogen metabolites
Xcalibur™ Quan Browser (Thermo Electron) was used to
quantitate the urine and tissue EM as previously
described [28,29]. Calibration curves for each EM were
constructed by plotting EM-Dansyl/SI-EM-Dansyl peak
area ratios obtained from calibration standards versus
amounts of EM injected on column and fitting these
data using linear regression with 1/X weighting. The
amounts of EM in sample were interpolated using this
linear function. Based on their similarity of structures
and retention times, 13C6-E2 was used as the internal
standard for E2;
13C6-E1 for E1; d3-E3 for E3, 16-ketoE2,
and 16a-OHE1; d3-16-epiE3 for 16-epiE3 and 17-epiE3;
d5-2-MeOE2 for 2-MeOE2, 4-MeOE2, 2-MeOE1, 4-
MeOE1, and 3-MeOE1; d5-2-OHE2 for 2-OHE2, 2-
OHE1, and 4-OHE1, respectively. All samples were run
in triplicate; in addition, approximately 1/3 of the sam-
ples analyzed were used for quality control or as calibra-
tion standards.
Metabolites recovery rate: the recovery rates in urine
were measured using quality control samples containing
0.12, 0.96, and 6.4 ng/mL of each estrogen metabolite;
the percent recovery ranged from 98-106%, 96-103%,
and 97-107%, respectively. The intra-batch precision, as
estimated from four replicate urine analyses at each
concentration level, was 2-5%, 1-5%, and 1-3% RSD for
the 0.12, 0.96, and 6.4 ng/mL control urine samples,
respectively. The lower limit of quantitation for each
estrogen is 0.02 ng/0.5 mL urine sample (2 pg on col-
umn). The limit of detection is 250 fg of each estrogen
metabolite on-column.
Assay reliability: The inter-assay variation coefficients
of the analytical method in urine, measured using the
lowest quality control standard containing 0.12 pg/mL of
each estrogen metabolite, range from a low of 3.8% for
16-epiE3 to a high of 12.1% for 16aOHE1. The intra-
assay variation ranges from a low of 2.1% for 4MeOE1 to
a high of 5.1% for 16aketoE2. In five serial tissue sections
cut from a lymph node infiltrated with metastatic breast
cancer [29], the coefficients of variation ranged from a
low of 2.4% for E1 to a high of 12.4% for 2-OHE2.
CYP1B1 genotype
Genomic DNA was extracted from buffy coats and ana-
lyzed for the presence of the G to C transversion at
codon 432 of the CYP1B1 gene by a PCR-based Restric-
tion Fragment Length Polymorphism (RFLP) assay. PCR
amplification of a 650 bp fragment of the CYP1B1 gene,
including part of exon 3 that contains the polymorphism
was carried out using forward primer: TCACTT
GCTTTTCTCTCTCC and reverse primer: AATTTC
AGCTTGCCTCCTG. Experimental details are described
elsewhere [11]. Restriction digestion of the DNA frag-
ment was carried out using Eco57I restriction enzyme.
The product of the restriction digest was mixed with
10 μl of loading dye and verified on a 3% agarose gel
(with Ethidium bromide) electrophoresis in a 1× Tris-
Borate-EDTA buffer at 200 V for 60 min. The presence
of a G at position 1294 (CYP1B1-codon 432) generated
a unique 650 bp fragments, while the 650 bp fragment
was divided into unique 340 bp and 310 bp fragments
when position 1294 contains a C. The gels were visua-
lized by UV light and the RFLP gel electrophoresis pro-
ducts were read by two independent persons.
Statistical analysis
Abundances of individual EM were summed to obtain
the 2-, 4-, and 16a-estrogen hydroxylation pathway
levels. The 2-hydroxylation pathway includes the 2-
hydroxyestrone, 2-hydroxyestradiol, 2-methoxyestrone,
2-methoxyestradiol, and 2-hydroxyestrone-3-methyl-
ether measures. The 4-hydroxylation pathway includes
4-hydroxyestrone, 4-methoxyestrone, and 4-methoxyes-
tradiol, and the 16a-hydroxylation pathway includes
16a-hydroxyestrone, estriol, 17-epiestriol, 16-epiestriol,
and 16-ketoestradiol. When comparisons between urine
and tissue are presented, the ratio of individual metabo-
lites to the entire levels of all estrogen recovered from
each compartment is calculated and expressed as per-
cent distribution.
Data are presented as mean ± SD; stratified data
according to CYP1B1 genotype are presented as mean ±
SE. The Kruskal-Wallis rank test was used to compare
overall averages from breast tissue and urine, and EM
across categories of CYP1B1 polymorphism. Compari-
sons between tissue and urine percent EM from each
subject was performed by paired t-test. All the analyses
were conducted using SAS v9.2 (Cary, NC).
Results
The general and clinical characteristics of breast cancer
cases included in this study are reported in Table 1.
Because of the inclusion criteria set up a priori, all the
cases were white non-smokers. Average age was 56.2 ±
10.2 years, average BMI was 31.5 ± 9.8 kg/m2; two
women claimed to be occasional drinkers of alcoholic
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beverages and seven reported to be in natural post-
menopause at the time of cancer diagnosis
Among the various EM measured in breast tissue and
urine (Table 2), percent estrogen levels (estrone, 17b-
estradiol) were significantly higher in breast tissue on
average than in urine. Average relative products of the
16-hydroxylation pathway were significantly lower in
breast tissue than in urine, and in this pathway 17-epies-
triol was undetectable in breast tissue. Several non-sig-
nificant differences between overall tissue and urine
values were observed: the 2-hydroxylation pathway was
less represented in breast tissue than urine, mostly
because of the complete absence of 2-hydroxyestrone
and 2-hydroxy-17b-estradiol in breast tissue as com-
pared to urine. Similarly, no components of the
4-hydroxypathway were detected in breast tissue, while
4-hydroxyestrone was measured in urine. The ratio
between the 2 and the 16 pathways was slightly higher
in breast tissue than in urine, although the difference
was not statistically significant. The sum of all EM levels
measured in tissue, but not in urine, significantly corre-
lated with BMI. No correlation with age was observed
for any metabolite.
The individual correspondence between relative values
measured in urine and breast tissue is shown in Figure
1. There was a statistically significant difference in
individual relative levels of estrogen, and products of the
16-hydroxylation between breast tissue and correspond-
ing urine obtained from the same subject; the general
pattern of the 2/16 ratio showed a correspondence
between urine and tissue; urine measurements showed
in general a much larger variability than tissue
measurements.
When data were stratified according to the CYP1B1
I462V polymorphism (Table 3), women carrying the var-
iant genotype (Leu/Val and Val/Val) showed signifi-
cantly lower average values of EM, estrogens, and
16-hydroxylation pathway levels in breast tissue in com-
parison to women carrying the wild type genotype. No
effect of the CYP1B1 polymorphism was observed in
urinary EM. The 2/16 ratio, either measured in urine or
in breast, was not significantly affected by the presence
of the CYP1B1 polymorphism.
Discussion
This study compared the levels of unconjugated estro-
gen metabolites in breast tissue and urine specimens
from the same individuals. To measure the complete
spectrum of EM, a highly sensitive liquid chromatogra-
phy-tandem mass spectrometry method was used.
Despite that fact that the sum of the EM levels was
similar between breast tissue and urine, the levels of
Table 1 Description of breast cancer cases included in the study
ID HISTOLOGY Age at diagnosis
(years)
Race Smoking Drinking Menopausal status BMI (Kg/m2) CYP1B1
(V432L) *
5 Intra Ductal Carcinoma 68 White Never Unknown Post 51.16 Wild type
8 Intra Ductal Carcinoma 45 White Never No Pre 38.39 Wild type
9 Intra Ductal and Lobular Carcinoma 51 White Never No Post 26.63 Wild type
1 Intra Ductal Carcinoma 44 White Never Yes Pre 22.49 Heterozygous
2 Intra Ductal Carcinoma 56 White Never No Post 37.12 Heterozygous
6 Intra Ductal Carcinoma 69 White Never No Post 35.51 Heterozygous
3 Intra Ductal Carcinoma 60 White Never No Post 21.45 Homozygous variant
4 Intra Ductal Carcinoma 67 White Never Yes Post 27.36 Homozygous variant
7 Metaplastic carcinoma 46 White Never No post 23.51 Homozygous variant
*SNP rs1056836
Table 2 Mean values of relative estrogen metabolites measured in breast tissue and corresponding urines
ESTROGEN METABOLITES
(% of total estrogen)
BREAST TISSUE
Mean ± SD
URINE
Mean ± SD
P value
(Kruskal-Wallis test)
Estrogens (estrone, 17b-estradiol) 53.4 ± 19.0 20.5 ± 18.4 0.02
2-Hydroxylation Pathway (*) 15.6 ± 8.7 21.4 ± 10.3 0.4
16-Hydroxylation Pathway (**) 30.9 ± 14.7 55.4 ± 17.8 0.02
4-hydroxyestrone (#) – 2.7 ± 2.0 N/A
2/16 ratio 0.61 ± 0.5 0.47 ± 0.34 0.45
pg/g wet tissue pg/mL
TOTAL 348.1 ± 188.8 337.4 ± 310.7 0.45
*2-hydroxyestrone-3-methyl ether was not detected in breast tissue or urine
**16-keto-17b-estradiol, 16-epiestriol were not detected in breast tissue or urine
#4-methoxyestrone, 4-methoxy-17b-estradiol were not detected in breast tissue or urine
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many of the individual components were quite different
between these two tissue sources. The sum of the estro-
gen levels (estrone, 17b-estradiol) was higher in breast
tissue than urine, while the metabolites of the 2 and the
16-hydroxylation pathways were lower. This result is
consistent with previous reports [7] suggesting rapid
conjugation of the products of 2 hydroxylation pathway
in tissues, followed by excretion in the urine. For the
catechol estrogen pathway, only the methoxylated meta-
bolites were detected in breast tissue, again suggesting
rapid methoxylation and excretion of tissue metabolites.
The metabolites of the 4 and 16 hydroxylation pathways
were also present in higher concentration in urine than
in breast tissue. It is clear that urinary and breast tissue
concentrations of specific estrogen metabolites reflect
the specific metabolic profile in tissue as well as the
degree of urinary excretion of each metabolite. It is pos-
sible that some of the metabolites detected in urine ori-
ginate from organs other than breast [30].
Two other studies have been published on EM mea-
surement in breast tissue from human subjects [31,32]
with the purpose of assessing differences between breast
cancer patients and healthy controls, but no individual
comparisons between breast tissue and urine has been
Figure 1 Individual comparison of EM measured in breast tissue and corresponding urine. A) Total metabolites, p value (paired t-test): 0.9.
B) Percent total estrogens (estrone, 17b-estradiol), p value (paired t-test): 0.005. C) Percent 16-hydroxylation Pathway, p value (paired t-test): 0.3.
D) percent 2-hydroxylation Pathway, p value (paired t-test): 0.02. E) 2/16 ratio), p value (paired t-test): 0.56. AV = average.
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performed so far. A comparison between the EM values
measured in our breast tissue samples with those
reported by the two publications is not feasible, since dif-
ferent laboratory methods were used for detection. Both
of these groups used high performance liquid chromato-
graphy with electrochemical detection to assess 11 conju-
gated estrogen derivatives. The present study used
LC-MS2 to measure 15 unconjugated products [33].
Aside from the detailed metabolic activities that might
lead to differences in breast tissue and urinary concen-
trations of specific estrogen metabolites, it is of interest
to compare the metabolite levels in the two tissue
sources, to determine the value of urinary measurements
as a surrogate biomarker of estrogen metabolite levels in
breast. The collection of urine for molecular epidemio-
logic studies represents a very simple approach which is
usually well accepted by the study participants; specifi-
cally, estrogen metabolites in urines have been used as
markers of susceptibility to breast cancer in healthy
women at high risk for breast cancer [34].
Our results suggest, in a small sample of women, that
the sum of the estrogen metabolite levels in urine do
reflect that formed in the target organ human breast tis-
sue, while this is much less true for most individual
metabolites. Among the various products measured, our
study showed that the 2/16 ratio was quite similar
between breast tissue and urine, thus supporting the use
of the ratio in urine as a surrogate tissue; it can be
therefore assumed that the urinary ratio measured in a
woman has a fair corresponds with the ratio that would
be measured in her breast tissue, if a biopsy could be
performed.
The production of estrone and 17b-estradiol has been
described to be under control of the CYP19 gene [35],
while CYP1B1 encodes for an enzyme that catalyzes the
formation of 2- and 4-hydroxyl estrone [7]. When the
presence of a common CYP1B1 polymorphism was
examined as a possible modifier of the EM levels in
breast and urine, we observed that the variant CYP1B1
allele was associated with lower total metabolites and
estrogen levels in breast tissue but not in urine. CYP1B1
is expressed in the breast as well as in kidney, prostate,
uterus, ovary and placenta from human subjects [7,36].
These observations suggest that metabolic genes may
have an important role in the estrogen metabolism
locally in tissues where the gene is expressed, a role that
is not readily observable when urinary measurements
are performed. The CYP1B1 genotype had no significant
effect on the 2/16 ratio in either breast tissue or urine,
thus highlighting the use of the 2/16 ratio as an inde-
pendent biomarker of breast cancer risk.
A complete profile of genotypes of genes regulating
estrogen metabolism in breast tissue would be useful in
further understanding individual differences in estrogen
metabolism in both the healthy breast and in breast can-
cer. Another aspect that still needs to be studied is the
validity of these findings in other ethnic groups. In fact,
the present study included a small sample of white
women only.
Conclusions
The urinary 2/16 ratio is a good approximation of the
ratio observed in breast tissue. Metabolic genes may
have an important role in the estrogen metabolism
locally in tissues where the gene is expressed, a role that
is not readily observable when urinary measurements
are performed.
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Table 3 Association between CYP1B1 Leu/Val
polymorphism and EM levels in breast tissue and urine
BREAST TISSUE
pg/g wet tissue
CYP1B1
Leu/Leu
Mean (SE)
CYP1B1
Leu/Val+ Val/
Val
Mean (SE)
p-value
(Kruskal-Wallis
test)
Estrogens# 373.7
(46.2)
117 (28) 0.02
2-hydroxylation
Pathway
54.7 (22.9) 43.9 (8.3) 0.79
16-hydroxylation
Pathway
141.8
(29.7)
76.1 (13.2) 0.07
Total* 570.5
(85.7)
237.0 (25.2) 0.02
2/16 ratio 0.39 (0.15) 0.73 (0.24) 0.31
URINE pg/mL
Estrogens 37.4 (11.7) 124.3 (81.2) 0.79
2-hydroxylation
Pathway
73.3 (39.6) 56.1 (19.2) 0.6
16-hydroxylation
Pathway
216.6
(81.5)
151.5 (84) 0.3
Total 341.8
(132.3)
335.5 (149.1) 0.6
2/16 ratio 0.34 (0.09) 0.54 (0.16) 0.43
*P value test for trend = 0.05
#P value test for trend 0.06
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